AI Article Synopsis
- Researchers created a genetically engineered protein cage (HspG41C-SP94) that targets human liver cancer cells (HCC) specifically.
- The protein cage was linked to the chemotherapy drug doxorubicin (DOX).
- This new treatment was as effective as standard DOX against cancer cells but caused less harm to normal liver cells.
Article Abstract
Herein, we report the preparation of genetically engineered protein cages (HspG41C-SP94), taken up selectively by human hepatocellular carcinoma (HCC) cells. An engineered protein cage-doxorubicin (DOX) conjugate was as cytotoxic as free DOX against HCC cells but much less cytotoxic against normal hepatocytes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c3cc44508a | DOI Listing |
Publication Analysis
Top Keywords
engineered protein
12
genetically engineered
8
human hepatocellular
8
hepatocellular carcinoma
8
hcc cells
8
nanocarrier based
4
based genetically
4
protein cage
4
cage deliver
4
deliver doxorubicin
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!